318 related articles for article (PubMed ID: 23028039)
1. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Livingston RB; Davidson NE; Perez EA; Chavarri-Guerra Y; Cameron DA; Pritchard KI; Whelan T; Shepherd LE; Tu D
Ann Oncol; 2013 Feb; 24(2):355-361. PubMed ID: 23028039
[TBL] [Abstract][Full Text] [Related]
2. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Jin H; Tu D; Zhao N; Shepherd LE; Goss PE
J Clin Oncol; 2012 Mar; 30(7):718-21. PubMed ID: 22042967
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
[TBL] [Abstract][Full Text] [Related]
4. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
[TBL] [Abstract][Full Text] [Related]
5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
6. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
[TBL] [Abstract][Full Text] [Related]
7. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
8. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Ingle JN; Tu D; Pater JL; Muss HB; Martino S; Robert NJ; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
Ann Oncol; 2008 May; 19(5):877-82. PubMed ID: 18332043
[TBL] [Abstract][Full Text] [Related]
9. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Goodwin RA; Jamal R; Booth CM; Goss PE; Eisenhauer EA; Tu D; Shepherd LE
Eur J Cancer; 2016 May; 58():97-103. PubMed ID: 26986765
[TBL] [Abstract][Full Text] [Related]
11. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
12. New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Liedke PE; Tu D; Shepherd L; Chavarri-Guerra Y; Pritchard KI; Stearns V; Goss PE
Breast; 2016 Jun; 27():99-104. PubMed ID: 27058233
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
15. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Scott LJ; Keam SJ
Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
[TBL] [Abstract][Full Text] [Related]
16. Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2011; 16(12):1762-70. PubMed ID: 22089970
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Moy B; Tu D; Pater JL; Ingle JN; Shepherd LE; Whelan TJ; Goss PE
Ann Oncol; 2006 Nov; 17(11):1637-43. PubMed ID: 16936184
[TBL] [Abstract][Full Text] [Related]
18. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
19. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Colleoni M; Giobbie-Hurder A; Regan MM; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Láng I; Smith I; Chirgwin J; Pienkowski T; Wardley A; Price KN; Gelber RD; Coates AS; Goldhirsch A
J Clin Oncol; 2011 Mar; 29(9):1117-24. PubMed ID: 21321298
[TBL] [Abstract][Full Text] [Related]
20. Continuing with letrozole offers greater benefits.
Jänicke F
J Cancer Res Clin Oncol; 2007 Jul; 133(7):445-53. PubMed ID: 17226047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
